ACNR is a UK-based, international, open access, peer reviewed neurology journal which aims to keep busy practicing specialists up-to-date with the latest advances in their fields.
Positive topline results from UCB MycarinG study investigating the efficacy and safety of rozanolixizumab in patients with generalised myasthenia gravis (gMG) Study met primary and all secondary endpoints with statistical significance Rozanolixizumab was well tolerated with no new observed safety signals UCB plans regulatory submissions for rozanolixizumab in gMG from Q3 2022 December 10th, 2021…
Sign up to receive our email newsletter with links to the latest content. ACNR is free, thanks to the support of advertisers. The editorial content is peer reviewed and remains completely independent unless clearly specified.
